welcome to

MYELOMA CLINICAL TRIALS

Data Driven Individualized Treatments for every patient
Pathway towards cure

MCT is a Myeloma Education Website to provide a seamless source of information for Myeloma community around the world.

Click on drug name to see associated clinical trials

Ciltacabtagene Autoleucel - Idecabtagene Vicleucel
Teclistamab - Talquetamab - Elranatamab
Bortezomib - Carfilzomib - Ixazomib
Daratumumab - Isatuximab - Elotuzumab
Lenalidomide - Pomalidomide - Thalidomide
Selinexor - Venetoclax
Other

NCT03710603 - A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy (Perseus)

N Engl J Med - Publication - January 25, 2024

Newly Diagnosed Multiple Myeloma Trials

Recruiting

NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6

EMN 28 European Myeloma Network EMN28/68284528MMY3005 NCT05257083: Phase 3 : A Study of Daratumumab, Bortezomib, Lenalidomide and...

Recruiting

NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM

SWOG - S2209 - Southwest Oncology Group NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma...

Recruiting

NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5

CARTITUDE-5 Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against...

Active

NCT04483739: Phase 3: EMN 24 - Isa-KRd vs KRd New Multiple Myeloma Eligible for ASCT - IsKia TRIAL

(IsKia TRIAL) (IsKia) - (EMN24/HOVON503) NCT04483739: Phase 3: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for...

Active

NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM (Perseus) EMN17

Perseus Study NDMM Newly Diagnosed Multiple Myeloma EMN 17 Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to...

Active

NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.

NDMM - DFCI 10-106 DETERMINATION Trial Delayed vs Early Transplant with Revlimid Maintenance and Anti-Myeloma Triple Therapy DFCI 10-106...

Relapsed & Refractory Multiple Myeloma Trials

Recruiting

NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma

NCT05259839: Phase 1: (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for Relapsed/Refractory Multiple Myeloma A Study to...

Active

NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)

bb2121 Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7) KarMMa-7 Relapsed & Refractory Multiple...

Recruiting

NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...

Active

NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

MajesTEC1 study A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1) Relapsed & Refractory...

Active

NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma

MagnetisMM-3 NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma Relapsed & Refractory...

Recruiting

NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM

(LINKER-MM1) RRMM First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma The primary objectives...

MGUS & Smoldering Myeloma Trials

Recruiting

NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma - NUTRIVENTION

NUTRIVENTION Study NCT04920084: A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or...

Recruiting

NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM

DETER-SMM EAA173 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma...

Recruiting

NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population

PROMISE NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population The PROMISE Study aims to...

Multiple Myeloma FAQ's: Frequently Asked Questions

Patient Education: Drugs

Patient Education: Lenalidomide - Immunomodulatory Agents - IMIDS

Patient Education: Revlimid (lenalidomide) - Immunomodulatory Agents - IMIDS LENALIDOMIDE (REVLIMID) NIH National cancer institute...

Patient Education: FAQ

IMF - International Myeloma Foundation: Patient Handbook 2022

IMF - International Myeloma Foundation: Patient Handbook 2022 Click here to view Patient Handbook Learn more: https://www.myeloma.org/pub...

Patient Education: FAQ

What are Multiple myeloma defining events? International Myeloma Working Group - SLiM-CRAB Criteria

What are Multiple myeloma defining events? International Myeloma Working Group - SLiM-CRAB Criteria What are myeloma defining events? ...

Myeloma Centers

Trials @ Levine Cancer Center

Trials @ MSKCC

Trials @ University of Miami

Chemotherapy Protocols

MYELOMA CLINICAL TRIALS

Multiple Myeloma Patient Education

welcome to

MYELOMA CLINICAL TRIALS

Data Driven Individualized Treatments for every patient
Pathway towards cure

Click on drug name to see associated clinical trials

Newly Diagnosed Multiple Myeloma Trials

Relapsed & Refractory Multiple Myeloma Trials

MGUS & Smoldering Myeloma Trials

Multiple Myeloma FAQ's: Frequently Asked Questions

Myeloma Centers

Trials @ Levine Cancer Center

Trials @ MSKCC

Trials @ University of Miami

welcome to

MYELOMA CLINICAL TRIALS

Data Driven Individualized Treatments for every patient Pathway towards cure

Data Driven Individualized Treatments for every patient
Pathway towards cure